73
Participants
Start Date
December 31, 2009
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
brentuximab vedotin
1.8 mg/kg IV every 21 days
rifampin
600 mg/day PO
midazolam
1 mg IV
ketoconazole
400 mg/day PO
brentuximab vedotin
1.2 mg/kg IV every 21 days
St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis
Karmanos Cancer Institute / Wayne State University, Detroit
Colorado Blood Cancer Institute, Denver
City of Hope, Duarte
Hackensack University Medical Center, Hackensack
Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY